Actuate Therapeutics ACTU 深 沪
等待开盘 08-16 09:30:00 美东时间
8.12
-0.100
-1.22%
华盛通- 最 高8.235
- 今 开7.98
- 成交量 4.34万股
- 最 低 7.76
- 昨 收 8.22
- 总市值 1.59亿
- 52周最高 11.99
- 市盈率 静 --
- 换手率 0.22%
- 52周最低 5.47
- 委 比 0.00%
- 总股本 1961.97万
- 历史最高 11.99
- 量 比 0.53
- 振 幅 5.78%
- 历史最低 5.47
- 每 手 1
- 风险率 1.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Actuate Therapeutics Q2 EPS $(0.30) Beats $(0.32) Estimate
Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.32) by 4.76 percent. This is a 92.86 percent increase over losses of $(4.20) per share
08-15 05:49
Actuate Therapeutics Initiates Phase 1b Trial Of Elraglusib In Combination With Incyte's PD-1 Inhibitor, Retifanlimab, And Modified FOLFIRINOX As Frontline Therapy In Advanced Pancreatic Adenocarcinoma
Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline TherapyCHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU)
08-06 20:47
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
Actuate Therapeutics initiates a Phase 1b trial of elraglusib in combination with Incyte’s PD-1 inhibitor retifanlimab and modified FOLFIRINOX as frontline therapy for advanced pancreatic adenocarcinoma. Conducted at UPMC Hillman Cancer Center, the trial aims to determine the recommended phase 2 dose (RP2D) and evaluate efficacy, safety, and tolerability. Anwaar Saeed, MD, highlights elraglusib’s potential to enhance immune responses and modulate...
08-06 12:45
Actuate Therapeutics shares are trading higher after the company announced it will initiate the planning of its Phase 2 trial of Elraglusib.
Actuate Therapeutics shares are trading higher after the company announced it w...
07-17 21:23
Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas
Actuate Therapeutics has completed Phase 1 of its elraglusib study in pediatric patients with refractory malignancies, showing promising results in treating Ewing Sarcoma (EWS). Among ten EWS patients, two achieved complete responses, two had stable disease, and one patient with desmoplastic small-round-cell tumor (DSRCT) saw a partial response. Actuate plans to initiate a Phase 2 trial in 2026 for relapsed/refractory EWS patients, targeting both...
07-17 12:45
Actuate Therapeutics Highlights Results From Pre-Specified Subgroup Analysis Of Phase 2 Trial Of Elraglusib In Combination With GnP In First-Line Metastatic Pancreatic Adenocarcinoma
- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus
06-24 21:22
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
Actuate Therapeutics reported Phase 2 trial results for elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic adenocarcinoma (mPDAC). Patients receiving at least one cycle of elraglusib/GnP achieved a median overall survival (mOS) of 12.5 months vs 8.5 months in the control arm, with a 43% reduction in death risk. Liver metastases patients saw a 2.5-fold improvement in 1-year OS and 38% reduced death ...
06-24 13:15
Actuate Therapeutics To Be Added To Russell 3000 Index, With Automatic Inclusion In Russell 2000 Index, Effective June 27
Inclusion reflects continued growth and momentum in the company's mission to transform the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)CHICAGO and FORT WORTH, Texas, June 16, 2025 (GLOBE NEWSWIRE) --
06-16 20:31
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Actuate Therapeutics has been added to the Russell 3000® and Russell 2000® Indexes, reflecting its growth and recent positive Phase 2 data for elraglusib in mPDAC, showing improved survival rates. This inclusion enhances the company's visibility and validates its platform for long-term growth.
06-16 12:30
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
Actuate Therapeutics announced positive results from its Phase 2 clinical trial of elraglusib combined with gemcitabine/nab-paclitaxel in untreated metastatic pancreatic ductal adenocarcinoma patients. The trial met its primary endpoint, showing a 10.1-month median overall survival (mOS) vs 7.2 months with GnP alone (p=0.01), a 37% reduced risk of death (HR=0.63). Twelve-month survival rates doubled to 44.1% in the elraglusib group. The event fea...
06-02 13:00
